The results are encouraging and we now need larger trials to understand whether the effects we saw in this study translate into long - term benefits, and to study how
psilocybin compares to other current treatments.»
Further research is now needed to tease out the relative influence of these factors on symptoms of depression, and look at how
psilocybin compares to placebo and other current treatments.
Not exact matches
In follow - up interviews conducted two months later 67 percent of the volunteers rated the
psilocybin experience as among the most meaningful of their lives,
comparing it to the birth of a first child or the death of a parent, and 79 percent reported that it had moderately or greatly increased their overall sense of well - being or life satisfaction.
The UBC Okanagan study found that 42 per cent of U.S. adult male inmates who did not take psychedelic drugs were arrested within six years for domestic battery after their release,
compared to a rate of 27 per cent for those who had taken drugs such as LSD,
psilocybin (commonly known as magic mushrooms) and MDMA (ecstasy).
The patients knew they were receiving
psilocybin (an «open - label» trial) and the effect of
psilocybin was not
compared with a placebo.
So the team at Ohio State
compared three types of shrooms containing
psilocybin with those that did not.
The studies, from New York University (29 patients) and Johns Hopkins University (51 patients), found that treatment with a single dose of
psilocybin, in combination with psychotherapy, led to an substantial reduction in depression and anxiety symptoms
compared to a placebo (a very low dose of
psilocybin.